Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2022 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
May 16, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
May 12, 2022 10:33 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
May 09, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3...
May 04, 2022 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
April 12, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

ZUG, Switzerland and CAMBRIDGE, Mass., April 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
April 07, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
March 08, 2022 16:35 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 28, 2022 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
February 15, 2022 16:01 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right